Ongoing clinical trials of human immunodeficiency virus latency-reversing and immunomodulatory agents

Open Forum Infectious Diseases

Volumn 3, Issue 4, 2016, Pages

  Delagrèverie, Héloïse M ^a   Delaugerre, Constance ^a   Lewin, Sharon R ^b,c   Deeks, Steven G ^d   Li, Jonathan Z ^e  

^a INSERM   (France)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Anti HIV agents; Clinical trial; HIV 1; Latency reversing agents; Viral reservoir

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; BRYOSTATIN 1; BUTYRIC ACID; DISULFIRAM; HYDROXYCHLOROQUINE; IMMUNOMODULATING AGENT; INGENOL; INTERLEUKIN 7; LATENCY REVERSAL AGENT; MARAVIROC; PANOBINOSTAT; PROGRAMMED DEATH 1 RECEPTOR; ROMIDEPSIN; TOLL LIKE RECEPTOR; TUCIDINOSTAT; UNCLASSIFIED DRUG; VALPROIC ACID; VIRUS RNA; VORINOSTAT;

CHRONIC INFLAMMATION; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MULTICENTER STUDY (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RNA TRANSCRIPTION; T CELL LYMPHOMA; VIRUS LATENCY;

EID: 84996539958     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofw189     Document Type: Review

References (97)

1. Colin L, Van Lint C. Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology 2009; 6:111
2. Kumar A, Darcis G, Van Lint C, Herbein G. Epigenetic control of HIV-1 post integration latency: implications for therapy. Clin Epigenetics 2015; 7:103
3. Barton KM, Archin NM, Keedy KS, et al. Selective HDAC inhibition for the disruption of latent HIV-1 infection. PloS One 2014; 9:e102684
4. McKernan LN, Momjian D, Kulkosky J. Protein kinase C: one pathway towards the eradication of latent HIV-1 reservoirs. Adv Virol 2012; 2012:805347
5. Jiang G, Mendes EA, Kaiser P, et al. Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cd-NF-κB signaling. AIDS; 28:1555-66
6. Jiang G, Dandekar S. Targeting NF-κB signaling with protein kinase C agonists as an emerging strategy for combating HIV latency. AIDS Res Hum Retroviruses 2015; 31:4-12
7. Barboric M, Nissen RM, Kanazawa S, et al. NF-kappaB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II. Mol Cell 2001; 8:327-37
8. Banerjee C, Archin N, Michaels D, et al. BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol 2012; 92:1147-54
9. Hoesel B, Schmid JA. The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer 2013; 12:86
10. Oh H, Ghosh S. NF-κB: roles and regulation in different CD4(+) T-cell subsets. Immunol Rev 2013; 252:41-51
11. Archin NM, Liberty AL, Kashuba AD, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012; 487:482-5
12. Rasmussen TA, Tolstrup M, Brinkmann CR, et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV 2014; 1:e13-21
13. Spivak AM, Andrade A, Eisele E, et al. A pilot study assessing the safety and latency- reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin Infect Dis 2014; 58:883-90
14. Elliott JH, McMahon JH, Chang CC, et al. Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. Lancet HIV 2015; 2:e520-9
15. Mann BS, Johnson JR, Cohen MH, et al. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007; 12:1247-52
16. Elliott JH, Wightman F, Solomon A, et al. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLoS Pathog 2014; 10:e1004473
17. Archin NM, Bateson R, Tripathy MK, et al. HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat. J Infect Dis 2014; 210:728-35
18. Ke R, Lewin SR, Elliott JH, Perelson AS. Modeling the effects of vorinostat in vivo reveals both transient and delayed HIV transcriptional activation and minimal killing of latently infected cells. PLoS Pathog 2015; 11:e1005237
19. Hayton EJ, Rose A, Ibrahimsa U, et al. Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial. PLoS One 2014; 9:e101591
20. Borthwick N, Ahmed T, Ondondo B, et al. Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol Ther 2014; 22:464-75
21. Ahmed T, Borthwick NJ, Gilmour J, et al. Control of HIV-1 replication in vitro by vaccine-induced human CD8(+) T cells through conserved subdominant Pol epitopes. Vaccine 2016; 34:1215-24
22. Jacobson JM, Routy JP, Welles S, et al. Dendritic cell immunotherapy for HIV-1 infection using autologous HIV-1 RNA: a randomized, double-blind, placebocontrolled clinical trial. J Acquir Immune Defic Syndr 2016; 72:31-8
23. Mahalingam D, Mita M, Sarantopoulos J, et al. Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors. Autophagy 2014; 10:1403-14
24. Kroon E, Ananworanich J, Eubanks K, et al. Effect of vorinostat, hydroxychloroquine and maraviroc combination therapy on viremia following treatment interruption in individuals initiating ART during acute HIV infection. In: International AIDS Conference 2016, 18-22 July 2016, Durban, South Africa. Available at: http://programme.aids2016.org/Abstract/Abstract/10535
25. Azzoni L, Foulkes AS, Papasavvas E, et al. Pegylated interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis 2013; 207:213-22
26. Sun H, Buzon MJ, Shaw A, et al. Hepatitis C therapy with interferon-a and ribavirin reduces CD4 T-cell-associated HIV-1 DNA in HIV-1/hepatitis C virus-coinfected patients. J Infect Dis 2014; 209:1315-20
27. Wightman F, Lu HK, Solomon AE, et al. Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells. AIDS 2013; 27:2853-62
28. Banga R, Procopio F, Cavassini M, Perreau M. In vitro reactivation of replication competent and infectious HIV-1 by HDAC inhibitors. J Virol 2015; 90:1858-71
29. Göttlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001; 20:6969-78
30. Lehrman G, Hogue IB, Palmer S, et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005; 366:549-55
31. Archin NM, Cheema M, Parker D, et al. Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLoS One 2010; 5:e9390
32. Routy JP, Tremblay CL, Angel JB, et al. Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study. HIV Med 2012; 13:291-6
33. Seki J, Ikeda R, Hoshino H. Dimethyl sulfoxide and related polar compounds enhance infection of human T cells with HIV-1 in vitro. Biochem Biophys Res Commun 1996; 227:724-9
34. Quivy V, Adam E, Collette Y, et al. Synergistic activation of human immunodeficiency virus type 1 promoter activity by NF-kappaB and inhibitors of deacetylases: potential perspectives for the development of therapeutic strategies. J Virol 2002; 76:11091-103
35. Golub EI, Li GR, Volsky DJ. Induction of dormant HIV-1 by sodium butyrate: involvement of the TATA box in the activation of the HIV-1 promoter. AIDS 1991; 5:663-8
36. McDonnel SJ, Sparger EE, Luciw PA, Murphy BG. Pharmacologic reactivation of latent feline immunodeficiency virus ex vivo in peripheral CD4+ T-lymphocytes. Virus Res 2012; 170:174-9
37. Del Prete GQ, Oswald K, Lara A, et al. Elevated plasma viral loads in romidepsin treated SIV-infected rhesus macaques on suppressive combination antiretroviral therapy. Antimicrob Agents Chemother 2015; 60:1560-72
38. Søgaard OS, Graversen ME, Leth S, et al. The depsipeptide romidepsin reverses HIV-1 latency in vivo. PLoS Pathog 2015; 11:e1005142
39. Leth S, Højen J, Schleimann M, et al. Effect of sequential Vacc-4x/GM-CSF immunization and romidepsin on the HIV reservoir. Abstract 26LB. In: Conference on Retroviruses and Opportunistic Infections CROI 2016, 22-25 February 2016, Boston, USA. Available at: http://www.croiconference.org/sessions/effect-sequential-vacc-4xgm-csfimmunization- and-romidepsin-hiv-reservoir
40. Caskey M, Klein F, Lorenzi JC, et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 2015; 522:487-91
41. Lu CL, Murakowski DK, Bournazos S, et al. Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science 2016; 352:1001-4
42. Schoofs T, Klein F, Braunschweig M, et al. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science 2016; 352:997-1001
43. Mehla R, Bivalkar-Mehla S, Zhang R, et al. Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PLoS One 2010; 5:e11160
44. Martínez-Bonet M, Isabel Clemente M, Jesús Serramía M, et al. Synergistic activation of latent HIV-1 expression by novel histone deacetylase inhibitors and bryostatin-1. Sci Rep 2015; 5:16445
45. Bullen CK, Laird GM, Durand CM, et al. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med 2014; 20:425-9
46. Darcis G, Kula A, Bouchat S, et al. An in-depth comparison of latency-reversing agent combinations in various in vitro and ex vivo HIV-1 latency models identified bryostatin-1+JQ1 and ingenol-B+JQ1 to potently reactivate viral gene expression. PLoS Pathog 2015; 11:e1005063
47. Gutiérrez C, Serrano-Villar S, Madrid-Elena N, et al. Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy. AIDS 2016; 30:1385-92
48. Abreu CM, Price SL, Shirk EN, et al. Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR. PLoS One 2014; 9:e97257
49. Warrilow D, Gardner J, Darnell GA, et al. HIV type 1 inhibition by protein kinase C modulatory compounds. AIDS Res Hum Retroviruses 2006; 22:854-64
50. Spivak AM, Bosque A, Balch AH, et al. Ex vivo bioactivity and HIV-1 latency reversal by ingenol dibenzoate and panobinostat in resting CD4(+) T cells from aviremic patients. Antimicrob Agents Chemother 2015; 59:5984-91
51. Jiang G, Mendes EA, Kaiser P, et al. Synergistic reactivation of latent HIV expression by ingenol-3-angelate, PEP005, Targeted NF-kB signaling in combination with JQ1 induced p-TEFb activation. PLoS Pathog 2015; 11:e1005066
52. Wang FX, Xu Y, Sullivan J, et al. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 2005; 115:128-37
53. Levy Y, Lacabaratz C, Weiss L, et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest 2009; 119:997-1007
54. Vandergeeten C, Fromentin R, DaFonseca S, et al. Interleukin-7 promotes HIV persistence during antiretroviral therapy. Blood 2013; 121:4321-9
55. Katlama C, Lambert-Niclot S, Assoumou L, et al. Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA: a randomized trial. AIDS 2016; 30:221-30
56. Lévy Y, Thiébaut R, Montes M, et al. Dendritic cell-based therapeutic vaccine elicits polyfunctional HIV-specific T-cell immunity associated with control of viral load. Eur J Immunol 2014; 44:2802-10
57. Brezar V, Ruffin N, Richert L, et al. Decreased HIV-specific T-regulatory responses are associated with effective DC-vaccine induced immunity. PLoS Pathog 2015; 11:e1004752
58. Scheller C, Ullrich A, Lamla S, et al. Dual activity of phosphorothioate CpG oligodeoxynucleotides on HIV: reactivation of latent provirus and inhibition of productive infection in human T cells. Ann N Y Acad Sci 2006; 1091:540-7
59. Novis CL, Archin NM, Buzon MJ, et al. Reactivation of latent HIV-1 in central memory CD4+ T cells through TLR-1/2 stimulation. Retrovirology 2013; 10:119
60. Sloan D, Irrinki A, Tsai A, et al. TLR7 agonist GS-9620 activates HIV-1 in PBMCs from HIV-infected patients on cART. Poster 417. In: Conference on Retroviruses and Opportunistic Infections CROI 2015, 23-26 February 2015, Seattle, USA. Available at: http://www.croiconference.org/sites/default/files/posters-2015/417. pdf
61. Whitney JB, Lim SY, Christa E, et al. Treatment with a TLR7 agonist induces transient viremia in SIV-infected ART-suppressed monkeys. Abstract 108. In: Conference on Retroviruses and Opportunistic Infections CROI 2015, February 23-26 2015, Seattle, USA. Available at: http://www.croiconference.org/sessions/treatment-tlr7-agonist-induces-transient-viremia-siv-infected-art-suppressedmonkeys
62. Winckelmann AA, Munk-Petersen LV, Rasmussen TA, et al. Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients. PLoS One 2013; 8:e62074
63. Offersen R, Nissen SK, Rasmussen TA, et al. A novel Toll-like receptor 9 agonist, MGN1703, enhances HIV-1 transcription and NK cell-mediated inhibition of HIV-1-infected autologous CD4+ T cells. J Virol 2016; 90:4441-53
64. Bhargavan B, Woollard SM, Kanmogne GD. Toll-like receptor-3 mediates HIV-1 transactivation via NFκB and JNK pathways and histone acetylation, but prolonged activation suppresses Tat and HIV-1 replication. Cell Signal 2016; 28:7-22
65. Xing S, Bullen CK, Shroff NS, et al. Disulfiram reactivates latent HIV-1 in a Bcl-2- transduced primary CD4+ T cell model without inducing global T cell activation. J Virol 2011; 85:6060-4
66. Doyon G, Zerbato J, Mellors JW, Sluis-Cremer N. Disulfiram reactivates latent HIV-1 expression through depletion of the phosphatase and tensin homolog. AIDS 2013; 27:F7-11
67. Said EA, Dupuy FP, Trautmann L, et al. Programmed death-1-induced interleukin- 10 production by monocytes impairs CD4+ T cell activation during HIV infection. Nat Med 2010; 16:452-9
68. Velu V, Shetty RD, Larsson M, Shankar EM. Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options. Retrovirology 2015; 12:14
69. Eron JJ, Gay C, Bosch RJ, et al. Safety, immunologic and virologic activity of anti-PD-L1 in HIV-1 participants on ART. Abstract 25. In: Conference on Retroviruses and Opportunistic Infections CROI 2016, 22-25 February 2016, Boston, USA. Available at: http://www.croiconference.org/sessions/safety-immunologicand- virologic-activity-anti-pd-l1-hiv-1-participants-art
70. Torino F, Barnabei A, Paragliola RM, et al. Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. Eur J Endocrinol Eur Fed Endocr Soc 2013; 169:R153-64
71. Jones R, Mueller S, O'Connor R. Cytotoxic T-lymphocytes in combination with the IL-15 superagonist ALT-803 eliminate latently HIV-infected autologous CD4+ T-cells from natural reservoirs. Short talk; Functional Eradication of HIV Reservoirs session, Keystone Symposia on Molecular and cellular biology, 26 April-1 May 2015, Boston, USA
72. Jones RB, Mueller S, O'Connor R, et al. A subset of latency-reversing agents expose HIV-infected resting CD4+ T-cells to recognition by cytotoxic T-lymphocytes. PLoS Pathog 2016; 12:e1005545
73. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011; 480:480-9
74. Klatt NR, Chomont N, Douek DC, Deeks SG. Immune activation and HIV persistence: implications for curative approaches to HIV infection. Immunol Rev 2013; 254:326-42
75. Barouch DH, Deeks SG. Immunologic strategies for HIV-1 remission and eradication. Science 2014; 345:169-74
76. Heredia A, Amoroso A, Davis C, et al. Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1. Proc Natl Acad Sci U S A 2003; 100:10411-16
77. Araki K, Turner AP, Shaffer VO, et al. mTOR regulates memory CD8 T-cell differentiation. Nature 2009; 460:108-12
78. Stock PG, Barin B, Hatano H, et al. Reduction of HIV persistence following transplantation in HIV-infected kidney transplant recipients. Am J Transplant 2014; 14:1136-41
79. Graf EH, Mexas AM, Yu JJ, et al. Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and off HAART. PLoS Pathog 2011; 7:e1001300
80. Hatano H, Yukl SA, Ferre AL, et al. Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers. PLoS Pathog 2013; 9:e1003691
81. Sáez-Cirión A, Bacchus C, Hocqueloux L, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013; 9:e1003211
82. Descours B, Avettand-Fenoel V, Blanc C, et al. Immune responses driven by protective human leukocyte antigen alleles from long-term nonprogressors are associated with low HIV reservoir in central memory CD4T cells. Clin Infect Dis 2012; 54:1495-503
83. Etemad B, Sun X, Lederman MM, et al. Viral and immune characteristics of HIV post-treatment controllers in ACTG studies. Abstract 347. In: Conference on Retroviruses and Opportunistic Infections CROI 2016, 22-25 February 2016, Boston, USA. Available at: http://www.croiconference.org/sessions/viral-and-immunecharacteristics- hiv-post-treatment-controllers-actg-studies
84. Shan L, Deng K, Shroff NS, et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012; 36:491-501
85. Graf EH, Pace MJ, Peterson BA, et al. Gag-positive reservoir cells are susceptible to HIV-specific cytotoxic T lymphocyte mediated clearance in vitro and can be detected in vivo [corrected]. PLoS One 2013; 8:e71879
86. Conway JM, Perelson AS. Post-treatment control of HIV infection. Proc Natl Acad Sci U S A 2015; 112:5467-72
87. Rouzioux C, Richman D. How to best measure HIV reservoirs? Curr Opin HIV AIDS 2013; 8:170-5
88. Bruner KM, Hosmane NN, Siliciano RF. Towards an HIV-1 cure: measuring the latent reservoir. Trends Microbiol 2015; 23:192-203
89. Murry JP, Tsai A, Graupe M, et al. Cyanotriazoles activate latent HIV and strongly synergize with proteasome inhibitors ex vivo in resting CD4T cells from suppressed HIV+ donors. Abstract OP7.3. In: HIV Persistence During Therapy Workshop, 8-11 December 2015, Miami, USA. Available at: http://www.hivpersistence. com/index.php/abstract
90. Bosque A, Macedo A, Spivak A, et al. Triazol-1-ol analogues as novel therapeutic leads towards reactivating and eradicating latent HIV-1 by manipulating SUMOylation of STAT5. Abstract OP7.4. In: HIV Persistence During Therapy Workshop, 8-11 December 2015, Miami, USA. Available at: http://www.hivpersistence. com/index.php/abstract
91. Bouchat S, Delacourt N, Kula A, et al. Sequential treatment with 5-aza-2'-deoxycytidine and deacetylase inhibitors reactivates HIV-1. EMBO Mol Med 2015; 8:117-38
92. Reuse S, Calao M, Kabeya K, et al. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One 2009; 4:e6093
93. Laird GM, Bullen CK, Rosenbloom DI, et al. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J Clin Invest 2015; 125:1901-12
94. Henrich TJ, Hu Z, Li JZ, et al. Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis 2013; 207:1694-702
95. Henrich TJ, Hanhauser E, Marty FM, et al. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med 2014; 161:319-27
96. Persaud D, Gay H, Ziemniak C, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 2013; 369:1828-35
97. Luzuriaga K, Gay H, Ziemniak C, et al. Viremic relapse after HIV-1 remission in a perinatally infected child. N Engl J Med 2015; 372:786-8